---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: MaGic"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: MaGic. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 92 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence/magic"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: MaGic

<a id="heading-3.1.2"></a>

## 3.1.2 MaGic

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.1-2"></a>

#### Objective of the randomized controlled period

> “To assess the safety and efficacy of subcutaneous claseprubart in patients with AChR Ab+ gMG.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.1-3"></a>

#### Objective of the top-line results abstract

> “To assess the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive (AChR Ab+) generalized Myasthenia Gravis (gMG).”
> “The MaGic study is the first study investigating the therapeutic potential of aC1s inhibitor in gMG.”

Source: [Peric et al. (2026b)](https://www.aan.com/msa/Public/Events/AbstractDetails/61545)

<a id="topic-3.1.2.1-4"></a>

#### Objective of the open-label extension analysis

> “Here, we report results from the ongoing MaGic study open-label extension.”
> “The primary assessment of the OLE is to evaluate the safety and tolerability of claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.1-5"></a>

#### Objective of the minimal symptom expression analysis

> “To assess achievement of MSE in SC Q2W claseprubart-treated gMG patients in the MaGic study versus placebo.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Recruitment status | “Active, not recruiting” |
| Study start (actual) | “2024-02-23” |
| Primary completion (actual) | “2025-07-28” |
| Study completion (estimated) | “2028-10” |
| First posted | “2024-02-28” |
| Last update posted | “2026-07-27” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.2-2"></a>

#### Number of locations and trial identifiers in the ClinicalTrials.gov record

> “This study has 56 locations”
> “DNTH103-MG-201 2024-512865-15-00 ( EU Trial (CTIS) Number )”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.2-3"></a>

#### Trial initiation after FDA clearance of the investigational new drug application

> “February 26, 2024 at 7:00 AM EST”
> “today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis”
> “The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.2-4"></a>

#### Global multicenter conduct

> “MaGic is a global, multicenter, randomized, double-blind, placebo- controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SC claseprubart (NCT06282159).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.2-5"></a>

#### Top-line results reported in September 2025

> “today announced positive top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody positive (AChR+) generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-2"></a>

#### Study periods in the ClinicalTrials.gov record

> “Screening (up to 10 weeks)”
> “Randomized, blinded, controlled treatment (RCT) period (13 weeks)”
> “Open-label extension (OLE) period (optional) for eligible participants (104 weeks)”
> “Safety follow-up (SFU) (40 weeks)”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-3"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.3-4"></a>

#### Randomization 1:1:1 to two claseprubart doses or placebo for 13 weeks

> “Patients with AChR Ab+ gMG were enrolled and randomized 1:1:1 to receive claseprubart 300mg (Q2W), claseprubart 600mg (Q2W), or placebo for 13 weeks, followed by an ongoing 52-week open-label extension and 40-week safety follow-up (Figure 2).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.3-5"></a>

#### Design described at the release of top-line results

> “The MaGic trial is a global, randomized, double-blind, placebo-controlled Phase 2 trial that enrolled 65 AChR+ participants with gMG.”
> “The initial randomized treatment duration was 13 weeks, followed by a 52-week open-label extension.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.3-6"></a>

#### Design planned at trial initiation

> “The MaGic trial is a global, randomized, double-blind, placebo-controlled Phase 2 study in up to 60 patients with generalized Myasthenia Gravis who are acetylcholine receptor (AchR) antibody positive.”
> “The S.C. treatment duration will initially be 12 weeks with a 52-week open label extension.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.3-7"></a>

#### Open-label extension entry, dosing, and follow-up of participants who declined

> “OLE-eligible patients must have completed the RCT without missing >1 dose. All patients entering the OLE received claseprubart 600mg Q2W for varying periods of time before the OLE dose was unified to 300mg Q2W following RCT analysis. Patients were assessed for safety and efficacy for up to 52 weeks. Patients who declined participation in the OLE were monitored for 40 weeks after the last study dose.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Study population summarized in the poster

> “Adults aged 18–75 years (inclusive) with a diagnosis of AChR Ab+ gMG, Myasthenia Gravis Foundation of American (MGFA) Class II-IVa at screening and randomization, and Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥6 at screening and randomization were eligible to participate in this study.”
> “Individuals with current or prior use of a complement inhibitor, use of an anti-FcRn agent within 90 days of randomization, use of rituximab within 6 months, or IVIg/PLEX within 4 weeks of randomization, or any known/ untreated thymoma were not permitted to participate in the study.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.4-2"></a>

#### Inclusion criteria: age, weight, diagnosis, disease class, and MG-ADL score

> “Adult males and females, 18 to 75 years of age (inclusive) at Screening.”
> “Weight range between 40-120 kg at Screening.”
> “Diagnosis of gMG by the following tests: Acetylcholine receptor antibody (AChR Ab) positive, and One of the following: i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.”
> “Myasthenia Gravis Foundation of America (MGFA) Class II-Iva”
> “Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or more”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-3"></a>

#### Inclusion criterion: meningococcal vaccination

> “Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-4"></a>

#### Exclusion criteria: infection history, viral infections, and thymic disease

> “Prior history (at any time) of N. meningitidis infection.”
> “Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening.”
> “Any thymic surgery/biopsy within 1 year of Screening.”
> “Any known or untreated thymoma.”
> “Any history of thymic carcinoma or thymic malignancy.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-5"></a>

#### Exclusion criteria: prior and concomitant therapy

> “Rituximab within 6 months (180 days) prior to randomization (Day 1)”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1).”
> “Participation in another clinical study of an investigational drug within 90 days or 5 half-lives of the investigational agent.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.4-6"></a>

#### Exclusion criterion: antinuclear antibody titer

> “An ANA titer of ≥1:320 was an exclusion criterion for the clinical trial protocol.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.4-7"></a>

#### Exclusion of prior C5 complement inhibitor use

> “Prior use of C5 complement inhibitors was exclusionary.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Day 1 | Week 1 to week 11 |
| --- | --- | --- |
| Placebo comparator: placebo | “Day 1: IV infusion of placebo” | “Week 1 to Week 11: placebo administered SC every 2 weeks” |
| Experimental: claseprubart 300 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |
| Experimental: claseprubart 600 mg Q2W | “Day 1: IV loading dose” | “Week 1 to Week 11: Claseprubart administered SC every 2 weeks” |

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.5-2"></a>

#### Intravenous loading dose followed by subcutaneous dosing every 2 weeks

> “Dosing: 15 or 20mg/kg I.V. Loading Dose followed by 300mg or 600mg S.C. Q2W starting Day 7”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.5-3"></a>

#### Loading dose by arm and subcutaneous volume

> “15 mg/kg for 300mg arm and 20 mg/kg for 600mg arm.”
> “Dosing: IV Loading Dose”
> “followed by 300mg/2mL or 600mg/4mL SC Q2W starting Day 7”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.5-4"></a>

#### Treatment described at the release of top-line results

> “Following an initial loading dose, claseprubart was administered every two weeks (Q2W) via subcutaneous (S.C.) injection at a dose of 300mg/2mL or 600mg/4mL.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.5-5"></a>

#### Open-label extension dosing for participants switching from placebo

> “Placebo patients switching over to OLE receive 600mg Q2W with no loading dose”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.5-6"></a>

#### Open-label extension dose unified to 300 mg every 2 weeks

> “Patients eligible for the 52-week OLE were switched to, or continued, Q2W 300 mg claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Registered primary outcome measure: treatment-emergent adverse events and serious adverse events to week 13

> “Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) Number of participants with TEAEs and treatment-emergent SAEs will be reported. Baseline (Day 1) to Week 13”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-2"></a>

##### Safety and tolerability as the primary endpoint

> “The primary endpoint of the study is safety and tolerability. Secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) score assessments.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-3.1.2.6.1-3"></a>

##### Primary, key secondary, and key exploratory assessments

> “The primary assessment for the study was to evaluate the safety and tolerability of claseprubart.”
> “Key secondary efficacy assessments included change from baseline in the MG-ADL Scale Score, the Quantitative Myasthenia Gravis (QMG) Scale score, and the Myasthenia Gravis Composite (MGC) Scale Score.”
> “Key exploratory assessments included achievement of minimal symptom expression (MSE; MG-ADL score ≤1), Myasthenia Gravis Composite Score (MGC), and Myasthenia Gravis Quality of Life 15- item scale (MG-QoL15r).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.6.1-4"></a>

##### Registered secondary outcome measures: long-term safety, serum concentrations, CH50, and antidrug antibodies

> “Incidence of TEAEs and Treatment-Emergent SAEs Number of participants with TEAEs and treatment-emergent SAEs will be reported. Through OLE completion, an average of 117 weeks”
> “Serum Concentrations of Claseprubart Blood samples will be collected for measurement of serum concentrations of claseprubart at various timepoints both pre- and post-dose.”
> “Change from Baseline in Complement Total Blood Test (CH50) Blood samples will be collected to determine changes in CH50 at various timepoints.”
> “Incidence and Titer of Antidrug Antibody (ADAs) Against Claseprubart Blood samples will be collected to measure ADA against claseprubart at various timepoints.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-5"></a>

##### Efficacy measure: Myasthenia Gravis Activities of Daily Living scale

> “The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-6"></a>

##### Efficacy measure: Quantitative Myasthenia Gravis score

> “The QMG is a clinician-reported assessment to evaluate muscle strength. The QMG consists of 13 items that measure endurance or fatiguability, with each item having a possible score that ranges from 0 - 3. The total possible QMG scores range from 0 - 39, with a higher score indicating greater disease burden.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-7"></a>

##### Efficacy measure: Myasthenia Gravis Composite scale

> “The MGC is a validated assessment tool for measuring clinical status of participants with MG. The range of total MGC score is 0 to 50, with higher scores indicating more severe disease. A clinically meaningful improvement is reflected by a 3-point improvement in MGC score. The MGC assesses 10 important functional areas most frequently affected by MG and the scales are weighted for clinical significance that incorporates patient-reported outcomes.”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.6.1-8"></a>

##### Efficacy measure: minimal symptom expression on MG-ADL and QMG

> “Here, we evaluated whether claseprubart use resulted in reaching minimal symptom expression (MSE), a measure of disease remission in gMG.”
> “MG-ADL-MSE was defined as achieving an MG-ADL score of 0 or 1.”
> “QMG-MSE was defined as achieving a QMG score of ≤3.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.6.1-9"></a>

##### Efficacy measure: revised 15-item Myasthenia Gravis Quality of Life scale

> “MG-QOL-15r, Myasthenia Gravis quality of life 15 revised.”
> “Secondary / Exploratory: Efficacy (MG-ADL, QMG MSE, MGC, MG-QoL-15r)”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned number of participants

> “Design: ~60 male and female subjects randomized to receive either claseprubart or placebo for 13 weeks”
> “Trial enrollment exceeded target, with 65 participants enrolled”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 65”

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants randomized and treated by arm

> “Sixty-five patients with AChR Ab+ gMG were randomized and received 300mg SC claseprubart (n=21), 600mg SC claseprubart (n=22), or placebo (n=22).”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants analyzed for MG-ADL minimal symptom expression at week 13

| Arm | Participants achieving MG-ADL MSE / analyzed |
| --- | --- |
| Placebo | “3/22” |
| Claseprubart 300 mg Q2W | “7/19” |
| Claseprubart 600 mg Q2W | “6/22” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.7.1-5"></a>

##### Participants in the pooled claseprubart group of the randomized period

> “Includes 21 patients who received claseprubart 300mg Q2W and 22 patients who received 600mg Q2W.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Mixed model for repeated measures for MG-ADL, QMG, and MGC

> “The change from baseline in MG-ADL was analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.”
> “The change from baseline in MGC and MGC Summed Muscle Score were separately analyzed using a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment by visit interaction, stratification factors, and baseline measure included.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-2"></a>

##### Logistic regression for minimal symptom expression and general linear model for MG-QoL-15r

> “The proportion of participants who achieve MSE was analyzed using a logistic regression with terms for treatment group, stratification factors, and baseline MG-ADL included.”
> “The change from baseline in MG-QoL 15r was analyzed using a general linear model with treatment group, stratification factors, and baseline measure included.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-3"></a>

##### One-sided and two-sided significance thresholds

> “One-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.1 considered nominally statistically significant.”
> “Two-sided p-values are presented for comparisons of claseprubart vs placebo, with any p-value below 0.05 considered nominally statistically significant.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.7.2-4"></a>

##### Adjusted logistic regression for MG-ADL and QMG minimal symptom expression

> “Adjusted analysis uses a logistic regression model with terms for treatment group, baseline and stratification factors.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.7.2-5"></a>

##### Dual MG-ADL and QMG responder definition and endpoints

> “A responder was defined as achieving an improvement in MG‐ADL ≥ 3 and QMG ≥ 4. Endpoints include proportion of dual MG‐ADL and QMG responders at Week 13, time to response, and proportion of responders sustaining response for at least 6 weeks.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.7.2-6"></a>

##### Pooled analysis of the two dose groups in the open-label extension

> “Since benefit/risk of 300mg and 600mg were similar in the RCT portion of the study, safety and efficacy data in the OLE are presented as pooled analyses.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Completion of the randomized controlled period and discontinuations by arm

| Measure | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Study discontinuations, n (%) | “1 (4.5)” | “1 (4.8)” | “0 (0)” |
| Due to AE, n (%) | “0 (0)” | “0 (0)” | “0 (0)” |

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.1-2"></a>

##### Sixty-three of 65 participants completed 13 weeks

> “Sixty-three of 65 patients completed the 13-week randomized controlled portion of the study. No patients discontinued due to adverse events (AEs) (Table 1).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.1-3"></a>

##### Discontinuations in the placebo and 300 mg arms

> “One placebo and one 300mg claseprubart patient discontinued, neither due to an adverse event.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.1-4"></a>

##### Entry into the open-label extension and duration of dosing

> “Sixty-three patients completed the 13-week RCT and 60 enrolled in the OLE (Table 1). The median time between first and last/latest dose in the OLE is 50 weeks.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographic and disease characteristics by arm

| Characteristic | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21) | Claseprubart 600 mg Q2W (N=22) |
| --- | --- | --- | --- |
| Age, mean (SD), years | “52.2 (16.5)” | “57.1 (13.7)” | “55.3 (12.0)” |
| Male, n (%) | “13 (59%)” | “14 (67%)” | “10 (45%)” |
| Weight, mean (SD), pounds | “195.0 (48.0)” | “192.5 (35.5)” | “179.0 (35.4)” |
| Duration of disease, median (range), years | “7.7 (0.4 – 21.2)” | “3.0 (0.5 – 22.1)” | “7.6 (1.0 – 37.3)” |
| MG-ADL score at baseline, mean (SD) | “8.5 (2.9)” | “8.2 (2.2)” | “8.4 (2.6)” |
| QMG score at baseline, mean (SD) | “14.2 (5.8)” | “12.2 (2.7)” | “12.2 (3.6)” |
| MG Composite score at baseline, mean (SD) | “15.0 (7.8)” | “16.3 (4.5)” | “16.0 (5.3)” |
| MG-QoL-15r score at baseline, mean (SD) | “14.3 (7.0)” | “15.4 (6.6)” | “14.9 (5.9)” |
| MGFA class II at screening, n (%) | “7 (32%)” | “11 (52%)” | “12 (55%)” |
| MGFA class III at screening, n (%) | “12 (55%)” | “10 (48%)” | “9 (41%)” |
| MGFA class IVa at screening, n (%) | “3 (14%)” | “0 (0%)” | “1 (5%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| One immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| More than one immunosuppressive therapy at baseline, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| FcRn use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.2-2"></a>

##### Balance across arms

> “Participant baseline characteristics were generally well balanced across arms”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.2-3"></a>

##### Overall sex, age, and disease duration

> “Approximately 57% of patients in the study were male with a mean age of 54.8 (standard deviation 14.1) years and a median disease duration of 5.6 years.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Week 13 efficacy summary by arm with placebo-adjusted differences

| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
| --- | --- | --- | --- | --- | --- |
| MG-ADL mean change from baseline | “-2.8” | “-4.6” | “-1.8 (P=0.0113)” | “-5.4” | “-2.6 (P=0.0006)” |
| QMG mean change from baseline | “-2.0” | “-4.4” | “-2.4 (P=0.0144)” | “-4.5” | “-2.5 (P=0.0111)” |
| MSE | “14%” | “37%” | “23% (P=0.0550)” | “27%” | “13% (P=0.1031)” |
| MGC mean change from baseline | “-3.1” | “-8.7” | “-5.6 (P=0.0008)” | “-8.6” | “-5.5 (P=0.0008)” |

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-2"></a>

##### MG-ADL change from baseline at week 13 by arm

> “Claseprubart dosed at 300mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.6 points in MG-ADL score at Week 13 (placebo-adjusted improvement: 1.8 points; P=0.0113).”
> “Claseprubart dosed at 600mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 5.4 points in MG-ADL score at Week 13 (placebo-adjusted improvement: 2.6 points; P=0.0006).”
> “As expected, there was no statistically significant difference between the claseprubart 300mg and 600mg arms in MG-ADL score at any time point.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-3"></a>

##### QMG change from baseline at week 13 by arm

> “Claseprubart dosed at 300mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.4 points in QMG score at Week 13 (placebo-adjusted improvement: 2.4; P=0.0144).”
> “Claseprubart dosed at 600mg S.C. Q2W achieved a statistically significant and clinically meaningful mean improvement from baseline of 4.5 points in QMG score at Week 13 (placebo-adjusted improvement: 2.5; P=0.0111).”
> “As expected, there was no statistically significant difference between the claseprubart 300mg and 600mg arms in QMG score at any time point.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.3-4"></a>

##### Two-sided P values for MG-ADL and QMG at week 13

| Measure | Claseprubart 300 mg Q2W vs placebo, two-sided P | Claseprubart 600 mg Q2W vs placebo, two-sided P |
| --- | --- | --- |
| MG-ADL | “P=0.0227” | “P=0.0013” |
| QMG | “P=0.0288” | “P=0.0222” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.3-5"></a>

##### Week 1 onset of MG-ADL and QMG improvement

> “Significant improvement from baseline in MG-ADL was observed as early as Week 1 in 300mg (p=0.0906 vs. placebo) and 600mg (p=0.0211) groups compared to placebo (one-sided p-values, p<0.1 considered nominally significant).”
> “Claseprubart produced rapid improvement as early as Week 1 (300mg [p=0.0042 vs. placebo]; 600mg [p=0.0418]) compared to placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-6"></a>

##### Improvement of 5 points or more on MG-ADL and QMG at week 13

> “Greater than 60% of patients achieved ≥5 point improvements in MG-ADL in both claseprubart dose groups at Week 13 (Figure 3B).”
> “At least 60% of patients achieved ≥5 point improvements in QMG in both claseprubart dose groups at Week 13 (Figure 3D).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-7"></a>

##### Dual MG-ADL and QMG responders at week 13

> “Results: 63% of claseprubart patients had dual response improvement in MG‐ADL ≥ 3 and QMG ≥ 4, versus 14% for placebo (OR 29.00; p = 0.0006). Dual responders were seen as early as Week 1. The median time to response was Week 3. All claseprubart patients with dual response at Week 13 had maintained response for at least 6 weeks.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.8.3-8"></a>

##### MG-ADL minimal symptom expression at week 13

> “At Week 13, significantly more patients from the 300mg claseprubart arm (37% [7/19], adjusted odds ratio (OR) 3.81, p=0.0550 vs. placebo) achieved MG-ADL-MSE compared to 14% (3/22) of placebo-treated patients (Figure 4A).”
> “Achievement of MG-ADL-MSE was rapid with 300mg claseprubart, beginning at Week 5 (OR 4.60, p=0.0358 vs. placebo).”
> “Median time to achieve MG-ADL-MSE was 3 weeks with 300mg claseprubart.”
> “Of the 300mg claseprubart-treated patients who achieved MG-ADL-MSE at Week 13, all demonstrated MSE for at least 6 consecutive weeks.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.3-9"></a>

##### QMG minimal symptom expression at week 13

> “QMG-MSE was achieved by significantly more 300mg claseprubart-treated patients at Week 13 (32% [6/19], OR 5.84, p=0.0387 vs. placebo) compared to placebo-treated patients (9% [2/22]) (Figure 4B).”
> “Median time to achieve QMG-MSE was 3 weeks with 300mg claseprubart.”
> “Of the 300mg claseprubart-treated patients who achieved QMG-MSE at Week 13, five of six patients demonstrated MSE for at least 6 consecutive weeks.”

Source: [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb)

<a id="topic-3.1.2.8.3-10"></a>

##### MG-ADL minimal symptom expression at week 13 in both dose groups

> “At Week 13, significantly more claseprubart-treated patients achieved MSE in the 300mg (36.8%; p=0.0550) compared to placebo (13.6%) (one-sided p-values, p<0.1 considered nominally significant).”
> “Twenty- seven percent of claseprubart 600mg patients achieved MSE at Week 13 though not significantly different from placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-11"></a>

##### MGC placebo-adjusted change with 80% confidence intervals

> “MGC scores were significantly improved from baseline to Week 13 in the 300mg (–4.1 placebo-adjusted [80% CI –6.0, –2.3]; p=0.0023 vs. placebo) and 600mg (–4.3 placebo-adjusted [80% CI –6.1, –2.5]; p=0.0016).”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-12"></a>

##### Post hoc subgroup with baseline QMG score of 10 or higher

> “MG-ADL improvement in the 300mg claseprubart arm (dose used in the upcoming Phase 3 study) was also assessed in patients with QMG score ≥10 at baseline. In this sub-group, the claseprubart 300mg arm (n=18) demonstrated greater improvement in MG-ADL score (–3.0 placebo-adjusted; p=0.0006) compared to the placebo arm (n=16) at Week 13.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.3-13"></a>

##### Open-label extension: sustained response through 65 weeks of treatment

> “Claseprubart patients who continued with Q2W claseprubart in the OLE demonstrated sustained improvement in MG-ADL (Figure 3A), QMG (Figure 3B), and MGC (Figure 3C) at OLE Week 52 compared to the end of RCT (65 total weeks on treatment).”
> “Rapid improvements in MG-ADL (Figure 3A), QMG (Figure 3B), MGC (Figure 3C) were observed as early as OLE Week 2 after switching from placebo to Q2W claseprubart.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.3-14"></a>

##### Open-label extension: change from extension baseline to week 52 in the MG-ADL, QMG, and MGC panels

> “Mean change from OLE baseline at Week 52: –0.8 for pooled claseprubart arm –3.3 for placebo to claseprubart arm”
> “Mean change from OLE baseline at Week 52: –0.1 for pooled claseprubart arm –4.5 for placebo to claseprubart arm”
> “Mean change from OLE baseline at Week 52: –1.4 for pooled claseprubart arm –5.5 for placebo to claseprubart arm”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.3-15"></a>

##### Open-label extension: week 4 response after switching from placebo

> “A robust MG-ADL decline at week 4 in the open-label extension (OLE) of -2.5 points and QMG score reduction of -3.2 points for patients on placebo during the RCT who received only two doses of claseprubart 600mg/4mL Q2W without a loading dose and achieved a PK level far below the steady state of 300mg/2mL Q2W, supporting potential for Q4W dosing of 300mg/2mL”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-3.1.2.8.3-16"></a>

##### Open-label extension: serum concentration after two 600 mg doses

> “PK of ~65 µg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 µg/mL”
> “Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks”

Source: [Dianthus Therapeutics presentation (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525262188/dnth-ex99_1.htm)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### MG-QoL-15r change from baseline at week 13 by arm with placebo-adjusted differences

| Measure at week 13 | Placebo (N=22) | Claseprubart 300 mg Q2W (N=21), absolute | Claseprubart 300 mg Q2W, placebo-adjusted (one-sided P) | Claseprubart 600 mg Q2W (N=22), absolute | Claseprubart 600 mg Q2W, placebo-adjusted (one-sided P) |
| --- | --- | --- | --- | --- | --- |
| MG-QoL-15r mean change from baseline | “-3.9” | “-6.1” | “-2.2 (P=0.0414)” | “-5.4” | “-1.5 (P=0.1122)” |

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.4-2"></a>

##### MG-QoL-15r change from baseline with standard deviations

> “Patient-reported quality of life (MG-QoL15r) was also significantly improved from baseline to Week 13 with 300mg claseprubart (–5.0 [SD 3.96]; p=0.0414) compared to placebo (–2.7 [SD 4.48]). The claseprubart 600mg group also showed improved MG-QoL15r scores at Week 13 (–4.2 [SD 3.85]; p=0.1122), which was not significantly different from placebo.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Safety and tolerability during the 13-week randomized controlled period

| Event, n (%) | Placebo (n=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Any treatment-related AEs | “13 (59.1)” | “15 (71.4)” | “21 (95.5)” |
| Clinical AEs | “11 (50.0%)” | “13 (61.9%)” | “15 (68.2%)” |
| Treatment-related serious AEs | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Infections | “10 (45.5%)” | “5 (23.8%)” | “6 (27.3%)” |
| Treatment-related serious infections | “1 (4.5%)” | “0 (0%)” | “0 (0%)” |
| Injection site reactions | “0 (0%)” | “2 (9.5%)” | “2 (9.1%)” |
| Newly positive for ANA | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-2"></a>

##### Table footnotes: clinical adverse events, injection site reactions, and antinuclear antibodies

> “Excludes events in the investigations System Organ Class (MedDRA).”
> “All injection site reactions were mild to moderate.”
> “Represents participants who were ANA negative at baseline and tested positive at ≥1:320 at any point during RCT (percentages calculated from n=17 for 300mg arm and n=22 for 600mg arm).”
> “At end of RCT (Week 13), 2 of the 8 patients in 600mg arm tested negative for ANA, 2 of the 8 patients in 600mg arm remained positive but at <1:320.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-3"></a>

##### Severity of treatment-related adverse events, serious adverse events, infections, and autoimmune activation

> “Claseprubart was generally well tolerated with a safety profile similar to the placebo group (Table 2).”
> “All treatment-related AEs with both doses of claseprubart were mild or moderate in severity, and no patients receiving claseprubart developed a serious AE related to treatment.”
> “No significant safety findings were observed regarding infections or autoimmune activation with either claseprubart dose group.”

Source: [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e)

<a id="topic-3.1.2.8.5-4"></a>

##### Discontinuation due to related adverse events in the randomized controlled period

| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| RCT discontinuation due to related AE | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

<a id="topic-3.1.2.8.5-5"></a>

##### Most common adverse events in more than 5% of participants in any arm

| Adverse event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Nasopharyngitis | “1 (4.5)” | “3 (14.3%)” | “3 (13.6)” |
| Lipase increased | “0 (0%)” | “3 (14.3%)” | “2 (9.1%)” |
| Upper respiratory tract infection | “3 (13.6%)” | “0 (0%)” | “1 (4.5%)” |
| Sinusitis | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Headache | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |
| Diarrhea | “2 (9.1%)” | “0 (0%)” | “0 (0%)” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-6"></a>

##### Myasthenia gravis exacerbations in the randomized controlled period

| Event, n (%) | Placebo (N=22) | Claseprubart 300 mg Q2W (n=21) | Claseprubart 600 mg Q2W (n=22) |
| --- | --- | --- | --- |
| Myasthenia gravis exacerbations | “2 (9.1%)” | “2 (9.5%)” | “2 (9.1%)” |

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-7"></a>

##### Definition and management of myasthenia gravis exacerbations

> “Defined as worsening of disease regardless of receiving rescue treatment. No patients required respiratory intervention and one patient in each arm received rescue treatment for the exacerbation.”
> “One patient had MG worsening attributed to missed Mestinon doses on the first day of claseprubart dosing (Day 1).”
> “All treatment-related adverse events in both claseprubart arms were mild or moderate in severity.”

Source: [Vu et al. (2026a)](https://investor.dianthustx.com/static-files/69412f75-384a-4ca8-9dab-aa518ad98126)

<a id="topic-3.1.2.8.5-8"></a>

##### Infections, autoimmune symptoms, and injection site reactions reported with top-line results

> “No infection signal was observed, including no related serious bacterial infections in the treatment arms; the only related serious adverse event (SAE) of infection occurred in the placebo arm.”
> “There were no symptoms indicative of autoimmune activation.”
> “Injection site reactions (ISRs) were infrequent and generally mild, and there were no claseprubart discontinuations from RCT due to related AEs.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-3.1.2.8.5-9"></a>

##### Injection site reaction severity in the top-line abstract

> “Injection site reactions were infrequent, mild to moderate, with the majority mild.”

Source: [Peric et al. (2026b)](https://www.aan.com/msa/Public/Events/AbstractDetails/61545)

<a id="topic-3.1.2.8.5-10"></a>

##### Open-label extension: adverse events through 52 weeks compared with the randomized controlled period

| Adverse event, n (%) | Randomized period: placebo (n=22) | Randomized period: pooled claseprubart (n=43) | Open-label extension: all claseprubart (n=60) |
| --- | --- | --- | --- |
| Clinical AEs | “11 (50.0)” | “28 (65.1)” | “45 (75.0)” |
| Related serious AEs | “1 (4.5)” | “0 (0.0)” | “1 (1.7)” |
| Discontinuation due to related AE | “0 (0)” | “0 (0)” | “1 (1.7)” |
| Infections | “10 (45.5)” | “11 (25.6)” | “28 (46.7)” |
| Related serious infections | “1 (4.5)” | “0 (0)” | “1 (1.7)” |
| Injection site reaction | “0 (0)” | “4 (9.3)” | “1 (1.7)” |
| Arthralgia | “1 (4.5)” | “1 (1.7)” | “4 (6.7)” |
| Myasthenia gravis exacerbation | “2 (9.1)” | “4 (9.3)” | “7 (11.7)” |

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.5-11"></a>

##### Open-label extension: table footnotes on the serious infection, discontinuation, and exacerbations

> “Patient with influenza who recovered and restarted claseprubart treatment (not considered related by sponsor).”
> “Patient with arthritis.”
> “Defined as worsening of disease regardless of receiving rescue treatment. No patients required respiratory intervention. During the RCT period two claseprubart patients received rescue treatment for the exacerbation and one patient had MG worsening attributed to missed pyridostigmine doses on the first day of claseprubart dosing (Day 1). During the OLE six patients received rescue therapy for the exacerbation.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.8.5-12"></a>

##### Open-label extension: consistency with the randomized period, meningococcal infections, and one death

> “Safety and tolerability of claseprubart in the OLE was consistent with the RCT, including no meningococcal infections.”
> “There was one death from a cardiovascular event deemed unrelated to claseprubart during the safety follow-up period in a 71-year-old male subject with a history of preexisting diabetes mellitus, hypertension, smoking, dyslipidemia and chronic obstructive pulmonary disease.”
> “Long-term treatment with claseprubart in the open-label extension demonstrated a sustained efficacy profile over 65 weeks with no new safety findings.”

Source: [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

MaGic is a phase 2 trial in which 65 participants with acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1:1 to claseprubart 300 mg every 2 weeks (21 participants), claseprubart 600 mg every 2 weeks (22 participants), or placebo (22 participants) for 13 weeks. The primary endpoint was safety and tolerability, measured as the incidence of treatment-emergent adverse events and serious adverse events to week 13; MG-ADL, QMG, and MGC were secondary endpoints, and minimal symptom expression and MG-QoL-15r were exploratory. Efficacy comparisons with placebo used one-sided P values, with values below 0.1 considered nominally significant, the MG-ADL result in participants with a baseline QMG score of 10 or higher came from a post hoc analysis of 18 and 16 participants, and the open-label extension pooled both dose groups without a placebo comparison after week 13. The results reported through November 2026 appear in company press releases and presentations and in congress posters and abstracts, and no peer-reviewed full article reporting the trial was identified.

Source: [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159); [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm); [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm); [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented); [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e); [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)

<a id="topic-3.1.2.9-2"></a>

#### Nominal significance threshold of one-sided P below 0.1

> “p ‐values are one‐sided, with nominal significance assessed at an alpha of 0.1.”

Source: [Dimachkie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310587/)

<a id="topic-3.1.2.9-3"></a>

#### Post hoc analysis of the subgroup with baseline QMG score of 10 or higher

> “This post hoc analysis is driving our decision to add a QMG inclusion criteria and a 300mg/2mL S.C. Q4W arm, in addition to a Q2W arm, in our Phase 3 MG study,”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-3.1.2.9-4"></a>

#### No QMG inclusion criterion in the phase 2 trial

> “Ph. 2 study did not include QMG inclusion criteria, similar to ravulizumab Ph. 3; post-hoc analysis of MaGic data demonstrates potentially best-in-class MG-ADL improvement in patients with QMG ≥10”

Source: [Dianthus Therapeutics presentation (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525262188/dnth-ex99_1.htm)

<a id="topic-3.1.2.9-5"></a>

#### No head-to-head comparison with other therapies

> “Safety and efficacy for claseprubart has not been evaluated in head-to-head comparative clinical studies.”

Source: [Dianthus Therapeutics presentation (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex992.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
